Midazolam and ropivacaine act synergistically to inhibit bone cancer pain with different mechanisms in rats

CHI-HUA GUO1*, LU BAI2*, HUANG-HUI WU3*, JING YANG4, GUO-HONG CAI5, SI-XIANG ZENG1, XIN WANG5, SHENG-XI WU5 and WEI MA1

Departments of 1Orthopedics and 2Medical Imaging, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061; 3Department of Anesthesiology, Fuzhou General Hospital of Nanjing Military Region, Fuzhou, Fujian 350025; 4Institute of Neuroscience, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058; 5Department of Neurobiology and Collaborative Innovation Center for Brain Science, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China

Received May 27, 2016; Accepted October 24, 2016

DOI: 10.3892/or.2016.5241

Abstract. Analgesic strategy of a single drug analgesia in bone cancer pain (BCP) has shifted to combined analgesia with different drugs which have different mechanism. After tumor cell inculation, the activation of signal transducer and activator of transcription (STAT3) and extracellular signal-regulated kinase (ERK) signaling pathway are involved in the development and maintenance of BCP, whereas a decrease in the expression of spinal STAT3 and ERK through using their specific blocker, lead to attenuation of BCP. Hence, in this study, we clarified that intrathecal (i.t.) injection of midazolam (MZL) and ropivacaine (Ropi) induces synergistic analgesia on BCP and is accompanied with different mechanisms of these analgesic effect. Hargreaves heat test was used to detect the analgesic effect of single dose of i.t. MZL, Ropi and their combination on the BCP rats. At consecutive daily administration experiment, thermal hyperalgesia was recorded, and immunohistochemical staining was used to detect the expression of c-Fos, spinal glial fibrillary acidic protein (GFAP) and ionized calcium binding adapter molecule-1 (IBA-1). Then, western blot analysis was used to examine spinal TSPO, GFAP, IBA-1, pERK/ERK and pSTAT3/STAT3 levels on day 14 after tumor cell inoculation. i.t. MZL or Ropi showed a short-term analgesia dose-dependently, and MZL displayed better effect on inhibition of pSTAT3 expression than pERK, but Ropi was just the reverse, then consecutive daily administrations of their combination acted synergistically to attenuate thermal hyperalgesia with downregulated spinal ‘neuron-astrocytic activation’ in the BCP rats. i.t. co-delivery of MZL and Ropi shows synergistic analgesia on the BCP with the inhibition of spinal ‘neuron-astrocytic activation’. Spinal different signaling pathway inhibition for MZL and Ropi may be involved in this process.

Introduction

Bone cancer pain (BCP) is a major clinical intractable problem, seriously affecting the lives of the patients (1). Despite increasing development of basic and clinical research for BCP, the novel clinical analgesics and advanced analgesic strategies often provide inadequate analgesia effect with unacceptable side-effects (2). Thus, in-depth studies are urgently needed for finding more effective and rational treatment strategy for cancer pain.

Recent basic studies in chronic neuropathic and inflammatory pain models suggests that peripheral nerve injury or local inflammatory stimulus results in the pathology changes of the spinal ERK and STAT3, whereas, the inhibition of both ERK and STAT3 contribute to attenuate hyperpathia (3–6). Midazolam (MZL), a short-acting and water-soluble benzodiazepine, is used as anesthetic for sedation, antianxiety, hypnosis of premedication, and induction and maintenance of general anesthesia (7). MZL is known as an adjuvant that has many advantages in clinical practice, such as quick effect and rapid inactivation (8). However, the unacceptable neurotoxicity
have been found at high doses of MZL, many studies confirm that i.t. MZL produce apoptosis of neurons, and these results restrict the wide use of MZL (9).

Ropivacaine (Ropi), a safe amino amide local anesthetic (LA), is widely used in local anesthesia and postoperative pain control, because it has less impact on motor function and fewer acceptable side-effects in a low concentration (10). However, repeated i.t. Ropi induces catastrophic neurotoxicity and neuronal apoptosis in a dose-dependent manner (11,12). Hence, how to amplify its analgesic effect and reduce the unacceptable side-effects becomes a new research area. Thus, the combination of two different drugs with different and/or overlapped mechanism was considered an effective and harmless method for analgesia in the clinic.

However, it is not clear that the synergistic analgesia of MZL and Ropi on BCP rats and those related underlying mechanisms. Based on the following evidence, we suggested that combination of MZL & Ropi might induce synergistic analgesia. First, Ropi as a block of fast voltage-gated sodium channels on neuronal axons is used as analgesia for many kinds of pain in basic experiments (13,14) and clinical trials (15,16). In our previous study, Ropi alleviated CFA-induced chronic inflammatory pain in rats, and combination with Ropi and Dex showed synergistic analgesia on the chronic inflammatory pain (14). Second, the increased expression of peripheral-type benzodiazepine receptors (PBRs), also named translocator protein, TSPO) are detected in astrocytes and microglia in inflammatory or nerve injury models (17,18). Ro5-4864, an agonist ligand of TSPO can attenuate pain behavior in neuropathic pain (21,22). Besides, analgesic effect of MZL has been confirmed by previous study in neuropathic pain (21,22).

Hence, using a model of BCP of female rats, we designed the current experiment to test that i.t. co-delivery of MZL and Ropi at lower dose yields synergistic analgesia, and further explore the underlying analgesic mechanisms of MZL and Ropi. It was found that these two clinically used drugs may be utilized in combination to achieve pain relief in BCP patients.

Materials and methods

Animal preparation. Adult female Sprague-Dawley (SD) rats, weighing 200-220 g, were provided by Experimental Animal Center of the Xi'an Jiaotong University. All rats were housed in controlled conditions (standard transparent plastic cages with a 12/12-h light/dark cycle, under 22-26°C ambient temperature with food and water ad libitum). All rats were allowed to adapt to the housing environment for at least 3 days before the experiments.

All experimental procedures were conducted in accordance with the Animal Use and Care Committee for Research and Education of the Xi'an Jiaotong University and National Institute for Physiological Sciences Animal Care and Use Committee. All efforts were made to minimize suffering of the animals and the number of animals used was carefully controlled.

Cell line and drug administration. Female SD rats were administered intraperitoneal (i.p.) inoculation of Walker 256 mammary gland carcinoma cells (2x10⁶ cells/ml, 1 ml). After 1 week, tumor cells were extracted from the cancerous ascitic fluid of rats, and resuspended in a concentration of 1x10⁷ cells/ml in 0.01 M phosphate-buffered saline (PBS) for inoculation.

MZL (5 mg/5 ml) and Ropi (100 mg/10 ml) were purchased from Nhwa Pharmaceutical Co., Ltd. (Jiangsu, China) and AstraZeneca AB (Sweden), respectively. These drugs were diluted with artificial cerebral spinal fluid (ACSF: NaCl 124 mM, D-glucose 10 mM, NaH₂PO₄ 1 mM, NaHCO₃ 25 mM, MgSO₄ 1 mM, KCl 4.4 mM and CaCl₂·H₂O 2 mM) prior to i.t. application. Finally, MZL (5 mg/5 ml) was diluted to concentrations (10 µg/ml), and the target concentrations of Ropi (100 mg/10 ml) was 1 mg/ml.

BCP model surgery. The inoculation was performed as previously described (23). Briefly, rats were anaesthetized with chloral hydrate (300 mg/kg, i.p.), the right rear hindlimb was shaved in order to expose the skin over the femoral-tibial joint. The intercondylar eminence of the right tibia was exposed after cleaning skin 3 times with iodine tincture and 75% ethanol. A 22-gauge needle was drilled into the site as described previously, then 20 µl microinjection syringe (Hamilton, USA) containing a 10 µl suspension of tumor cells was used to inject the tumor cells into the tibial cavity slowly. The drilled hole was sealed with bone wax (Johnson & Johnson, USA) in order to prevent tumor cells from spreading outside the bone. For the sham group, 10 µl PBS replaced tumor cells into the tibia (5).

Intrathecal implantation. Intrathecal implantation was performed under chloral hydrate (300 mg/kg, i.p.). Briefly, a midline incision (3 cm) was cut on the back of the rat at the level of the thoracic vertebrae. A pre-measured length of PE-10 tubing was passed caudally from the T8 to the L3 level of the spinal cord, fixed at the back of rat's ears through subcutaneous tunnel, and 2 cm of the free end was exposed in the upper thoracic region. Rats were allowed to recover for a period of 3-5 days before further use. The animals judged as with no neurological deficit and that presented complete paralysis of the tail and bilateral hind legs after administration of 2% lidocaine (10 µl) through the intrathecal catheter were used for the following experiments.

Behavioral test. Thermal hyperalgesia was evaluated by Hargreaves test. In brief, rats were placed individually in crylic boxes with wire mesh floors and allowed to adapt for 30 min. The radiant heat stimulator was used to stimulate the plantar surface of the hindlimb paw, and the intensity of the beam was set to produce a basal paw withdrawal latency (PWLo) of approximate 16 sec. The PWLo were recorded according to previous studies above. To prevent tissue thermal burn, the cut-off value was set at 20 sec. The blinding method was implemented strictly for the whole behavioral test.

Motor coordination was determined using a standard rat rotaord test (Shanghai Mobiledatum Information Technology Co., Ltd., China). Daily training for each rat was performed at 30 min after intrathecal administration of compound for 7 days, and measured as following methods: rats were placed on the rotating drums and the time was measured from the
start of the acceleration period until the rat fell off the drum. A cut-off latency was 30 sec in all rotarod assessments. The time that the animal remained on the rotarod was recorded and expressed as a percentage of its own baseline value.

**Immunofluorescence histochemistry staining.** Rats were deeply anesthetised with overdose chloral hydrate (10%, 0.3 ml/100 g) and transcardially perfused with 200 ml of 0.01 M PBS (pH 7.4), followed by 500 ml of 4% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4). The L4-L6 spinal cord segments were harvested and dehydrated in 30% sucrose at 4°C. Transverse spinal sections (30 µm thickness) were then cut on a cryostat (CM3050S, Leica, Germany). For double immunofluorescence, the sections were incubated with mouse anti-c-Fos (1:500, Abcam, USA), mouse anti-GFAP (1:500, Millipore, USA) and goat anti-IBA-1 (1:500, Abcam), followed by FITC-conjugated secondary antibodies (1:500, Invitrogen, USA) for 3 h at room temperature. The stained sections were observed and captured with a confocal laser scanning microscope (FV1000, Olympus, Japan).

**Western blot analysis.** The L4-L6 spinal cord segments were rapidly extracted from anesthetized rats. The tissues were homogenized in lysis buffer (Bio-Rad Laboratories, USA) which contains a mixture of protease inhibitors and phenylmethylsulfonyl fluoride (Roche Diagnostics, Switzerland). Equivalent amounts of protein (10 µl) were loaded and separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10% SDS-PAGE; Bio-Rad), transblotted onto PVDF membranes (Millipore). The membrane was incubated with primary antibody overnight at 4°C, followed by HRP-conjugated secondary antibodies for 2 h (1:5000, CST). The secondary antibody signal was detected and expressed as a percentage of its own baseline value.

**Statistical analysis.** All data were expressed as mean ± standard error mean (SEM), and analyzed by researchers with Graph-Pad Prism 6.0 using Graph-Pad software, San Diego, CA, USA. Isobolographic analysis was based on Tallarida and our previous study (24). P<0.05 was considered as statistically significant.

**Results**

**Effect of i.t. MZL on BCP.** In order to identify the potential analgesic effect of MZL in BCP, different doses of MZL were injected on day 14 after tumor cell inoculation. Based on previous studies, MZL was given in doses of 10, 20, 40 and 80 ng and PWLs were measured at 30, 60, 90, 120, 150 and 180 min post-injection of MZL and vehicle. Compared with BCP-Veh group, i.t. MZL significantly elevated PWLs in a dose-dependent manner with a peak effect at dose of 80 ng/kg at 60 min post-injection (Fig. 1A and B; P<0.01). The ED_{50} for MZL was calculated as 22.6 ng/kg based on the log (dose) vs. response curve (Fig. 1C and D; P<0.01). Besides, the rota rotarod test revealed 22.6 ng/kg MZL did not affect the motor performance of rats compared to vehicle treatment at any of the time-points tested (Fig. 1E; P<0.01). Hence, i.t. MZL inhibited thermal hyperalgesia in BCP rats.

**Effect of i.t. Ropi on BCP.** According to our previous studies (14), increasing doses of Ropi were given in 12.5, 25, 50 and 100 µg/kg and PWLs were recorded at 30, 60, 90, 120, 150 and 180 min post-injection of Ropi and vehicle. Compared with BCP-Veh group, i.t. Ropi also significantly elevated PWLs in a dose-dependent manner with a peak effect at dose of 100 µg/kg at 30 min post-injection (Fig. 1E and F; P<0.01). The ED_{50} for Ropi was calculated as 43.3 µg/kg based on the log (dose) vs. response curve (Fig. 1G and H; P<0.01). Similarly, the rota rotarod test also revealed 43.3 µg/kg Ropi did not affect the motor performance of rats compared to vehicle treatment at any of the time-points tested (Fig. 1E; P<0.01). Hence, i.t. Ropi apparently inhibits thermal hyperalgesia in a dose-dependent manner in BCP rats.

**Effect of i.t. MZL and Ropi combination on BCP.** Next, we calculated synergistic analgesic effect of MZL&Ropi on the basis of the antinociceptive effects showed by two drugs. According to additive regression, we calculated theoretical ED_{50} for a fixed-ratio (1:1) combination of MZL and Ropi. Hence, the doses of MZL&Ropi combinations were as follows: 8.66 Dex + 4.52 Ropi (ED_{50add*2/10} Dex&Ropi), 9.04 Dex + 17.32 Ropi (ED_{50add*1/10} Dex&Ropi) and 18.08 Dex + 34.64 Ropi (ED_{50add*8/10} Dex&Ropi).

PWLs were measured at 30, 60, 90, 120, 150 and 180 min post-injection of MZL&Ropi and vehicle, i.t. MZL&Ropi combination significantly elevated PWLs in a dose-dependent manner with a peak effect at dose of 18.08 Dex and 34.64 Ropi at 60 min post-injection (Fig. 2A and B; P<0.01). Besides, the averaged valid analgesic duration was significantly dose-dependently prolonged. The experimental ED_{50comb} at this fixed dose ratio calculated from these dose-response curves for pain responses was 6.61 MZL + 12.67 Ropi (Fig. 2C; P<0.01). Isobolographic analysis showed that MZL&Ropi acted synergistically to inhibit BCP in rats, because ED_{50comb} was smaller than the lower (95%) range of ED_{50add} (Fig. 2F; P<0.05). These results revealed that the combination of MZL&Ropi facilitated to prolong analgesic duration and enhance analgesic intensity with less dose of MZL and Ropi. The combination of MZL&Ropi did not affect motor coordination of the animals (Fig. 2E; P<0.01).

**Continuous analgesia of i.t. MZL&Ropi on BCP.** Above the effect of i.t. MZL, and Ropi, or their combination was described...
in a short-term observation. Then, their analgesia on BCP induced chronic hyperalgesia was further explored. According to \( \text{ED}_{50} \) MZL, \( \text{ED}_{50} \) Ropi, and \( \text{ED}_{50\text{comb}} \) Dex\&Ropi, the dose regimens were as follows: BCP-MZL group, 22.6 ng/kg MZL; BCP-Ropi group, 43.3 \( \mu \)g/kg Ropi; and BCP-MZL\&Ropi group, 6.61 ng/kg MZL and 12.67 \( \mu \)g/kg Ropi.
A significant analgesic effect of all intervention groups was observed. Compared with BCP-Vehicle group, i.t. MZL, Ropi, or their combination significantly increased the PWLs. In these three group, BCP-MZL&Ropi groups performed better analgesic effect than the others, however, analgesic effect of BCP-MZL group gradually attenuated with time. These results

Figure 2. i.t. MZL and Ropi combinations dose-dependently inhibit thermal hyperalgesia in bone cancer pain. Analgesia effects of different doses of i.t. MZL and Ropi combinations are shown (A). The AUC of i.t. MZL and Ropi combinations was observed (B). MZL and Ropi combinations dose-dependently inhibited thermal hyperalgesia with the dose-effect (C) and EC$_{50}$ (D). The effects of i.t. MZL and Ropi combinations on motor performance in normal rats (E). Isobologram for combination analgesia is presented (F). Long-term analgesia effect of i.t. MZL, Ropi, or their combination on bone cancer pain during 8 days after tumor cell inoculation, respectively (G). *P<0.05; **P<0.01. Compared with BCP-Veh group. ##P<0.01. Compared with BCP-MZL&Ropi group.
suggested that i.t. MZL&Ropi combination showed better analgesic effect in a long-term treatment in BCP rats with less doses and longer duration than each single drug (Fig. 2F; P<0.05).

Expression of spinal TSPO, pERK and pSTAT3 in BCP. We examined the time course of spinal GFAP, IBA-1, TSPO, pERK and pSTAT3 expression by western blot analysis. Western blot analysis revealed that spinal sustained elevation of GFAP could be detected in chronological order, and was accompanied by the development of behavioral hypersensitivity (Fig. 3A and B; P<0.05). In sharp contrast, the significant peak value of IBA-1 was not observed on day 14, but only on day 7 (Fig. 3A and C; P<0.05). Similar to GFAP expression, the expression of TSPO was significantly increased from
day 3 to 14, and reached its peak on day 14 (Fig. 3A and D; 
P<0.05). Then, the significant up-regulation of spinal pERK 
induced by tumor cell inculation was observed on day 7 
(Fig. 3A and E, P<0.05). However, spinal pSTAT3 expression 
was significantly activated on day 5 compared with the sham 
group (Fig. 3A and F, P<0.05).

Effect of i.t. MZL, Ropi or their combination on neuronal 
and glial activation. 
Increasing evidence has confirmed that 
spinal neuron-astrocytic activation played a vital role in BCP 
rat models. Hence, we further explored whether the inhibition 
of neurons and neuroglia cells contributed to analgesia at 
doses of ED50 MZL, ED50 Ropi, or ED50comb MZL&Ropi which 
achieved equal 50% analgesia.

We administered i.t. ED50 MZL, ED50 Ropi, or ED50comb 
MZL&Ropi once daily from day 7 to 14 to observe the effects 
on astrocytic and microglia activation in BCP rats on day 14. 
Western blot analysis confirmed that the increased GFAP 
expression could be inhibited by each intervention group 
compared with BCP group. However, the GFAP expres 
sion for BCP-MZL&Ropi group was less than the other two 
intervention groups, while there was no group difference 
between BCP-MZL and BCP-Ropi groups (Fig. 5A and B, 
P<0.05). Interestingly, the IBA-1 expression for BCP-MZL 
and BCP-Ropi groups was inhibited by each intervention, 
but there was no significant difference between BCP and 
BCP-MZL&Ropi groups. Compared with BCP-MZL and 
BCP-Ropi groups, i.t. MZ&Ropi combine did not inhibit 
IBA-1 expression (Fig. 5A and C, P<0.05).

In addition, immunohistochemistry showed increased nuclei 
expression of c-Fos on day 14 in BCP group. In each 
intervention group, the c-Fos expression was inhibited by two drugs 
respectively or combination (Fig. 4A). Immunohistochemical 
expression of GFAP and IBA-1 were similar to western blot 
results (Fig. 4B and C). These results indicated that a synergistic 
effect, which was also observed in previous behaviour tests, 
could be contributed by astrocytes, but not microglia.

Effect of i.t. MZL, Ropi or their combination on pERK and 
pSTAT3 expression. 
Next, we administered i.t. ED50 MZL, 
ED50 Ropi, or ED50comb MZL&Ropi once daily from day 7 to 14 
to observe the effects on pERK and pSTAT3 activation in SDH 
on day 14. Analysis of the pERK expression inhibited by each 
intervention group was compared with BCP group. However, 
the pERK expression for BCP-Ropi and BCP-MZL&Ropi 
groups were less than BCP-MZL groups, and there was no 
group difference between BCP-Ropi and BCP-MZL&Ropi 
groups (Fig. 5A and D, P<0.05). The pSTAT3 expression 
inhibited only by BCP-MZL group compared with BCP group, 
but there was great significant difference between BCP-Ropi 
and BCP-MZL&Ropi groups. The inhibition of pSTAT3 was 
the strongest in BCP-MZL group, compared with BCP-Ropi 
and BCP-MZL&Ropi group (Fig. 5A and E, P<0.05). These 
results indicated that i.t. MZL could inhibit pSTAT3 expres 
sion much better than i.t. Ropi, and i.t. Ropi was just the 
opposite compared with MZL, i.t. Ropi showed better inhibi 
tion of pERK than i.t. MZL. Based on previous behavior tests 
on intervention groups, we suggest that analgesia effect of MZL
could be contributed to inhibition of pSTAT3, and analgesic effect of Ropi was relevant to inhibition of pERK, furthermore, analgesic effect of MZL and Ropi combination could result from pERK inhibition, because it had stronger inhibitory effect on pERK expression compared with pSTAT3.

Discussion

Our study showed that MZL and Ropi reduced thermal hyperalgesia in a dose-dependent manner in BCP rats, respectively. Even more importantly, the low dose combination of MZL and Ropi acted synergistically to reduce thermal hyperalgesia after tumor cell inoculation. Next, we found that spinal neuron-astrocytic activation played a vital role in BCP rats. MZL dominantly downregulated the level of pSTAT3 while Ropi inhibited the spinal pERK expression. Therefore, the combined use of MZL and Ropi might be a new therapeutic approach for treatment of BCP.

Recent studies report that benzodiazepine receptor consists of two types of receptors, one is central-type benzodiazepine receptor located in the brain, and the other is peripheral benzodiazepine receptor located in the periphery.

Figure 5. Effect of i.t. Dex, Ropi, or their combination on spinal GFAP, IBA-1, pERK and pSTAT3 in BCP rats. Western blot analysis of GFAP, IBA-1, pERK and pSTAT3 expression on day 14 after tumor cell inoculation is shown (A). Results of western blot analysis are presented (B-E). *P<0.05; **P<0.01.
diazepine receptor (CBRs), which are coupled to type A γ-aminobutyric acid (GABA_A) receptor, and the other is peripheral-type benzodiazepine receptors (PBRs, also named translocator protein, TSPO), and these two types of receptors are the targets for MZL by increasing GABA release (20). Compared with CBRs that are expressed exclusively in the central nervous system (CNS), low expression of TSPO in CNS are common in normal condition. However, studies have shown that increased expression of TSPOs in both astrocytes and microglia are generally accompanied by neuroglia activation during the nociceptive stimulation, such as inflammation, CNS injury and pain (25,26). Moreover, Ro5-4864, an agonist of TSPO, but not TSPO antagonist PK11195, can attenuate the pain behavior in a dose-dependent manner that is contributed to suppress the astrocytic activation (17,27,28). In this study, similar results were confirmed: TSPO was upregulated in the SDH on day 14 after tumor cell incubation. The single i.t. administration of MZL dose-dependently inhibits thermal hyperalgesia in BCP rats, indicated that spinal astrocytic upregulation of TSPO induced by tumor cell incubation was involved in the analgesic effect of MZL.

Ropi, one of the newest and safest LAs, is widely used for local anesthesia in clinic. However, its relative neurotoxicity limits the clinical use. Accumulative evidence indicates that Ropi is considered as an effective drug in many kinds of pain models, such as CFA-induced chronic inflammatory pain and neuropathic pain (14,29). The analgesic effect of Ropi is contributed to inhibition of the overexpression of spinal c-Fos and GFAP in neuropathic pain that is consistent with previous electrophysiological results. In our study, Ropi dose-dependently attenuated thermal hyperalgesia in the BCP model, together with consequent observations on suppressing spinal neurons and neuroglia activation with the downregulation of spinal pERK.

In our study, the potential synergistically analgesic mechanisms of MZL and Ropi might be as follows. First, many researchers have confirmed that the TSPO upregulation was an endogenous protective response during the process of inflammatory stimulus and/or nerve injury, and MZL binds TSPO to reinforce this ‘protective shield’ and promotes its analgesic effect (17). TSPO mainly locates on the outer membrane of mitochondria which are the source of reactive oxygen species (ROS), and MZL suppresses the production of ROS and attenuates ROS-induced nerve injury (30). Furthermore, dimethylthiourea, one of ROS scavengers, has the ability to inhibit STAT3 activation induced by focal cerebral ischemia-reperfusion injury in rats (31). Hence, it is possible that MZL inhibit spinal pSTAT3 expression through suppression of ROS production via spinal activation of TSPO. A study of rat glial cell immune inflammation showed that MZL inhibited the release of IL-6 from rat C6 glioma cells by inhibiting astrocytic pSTAT3 activation in TSPO dose-dependently, while increased level of IL-6 and activation of STAT3 have been considered as trigger for initiation and maintaining of pain (20,32). We also found that MZL could obviously inhibit pSTAT3 activation.

Second, spinal pERK activation plays a crucially role in the maintenance of many kinds of pain, such as nerve injury and inflammation, and participates in regulating astrocytic activation and proliferation (33,34). In BCP model, spinal pERK activation was mainly expressed in neurons, but not in microglia and astrocytes in the early phase. However, in the late phase, spinal pERK expression was mainly located in astrocytes (4). In our study, we found that Ropi could down-regulate spinal pERK expression with significant inhibition of neurons and neuroglia cells activation.

Third, based on the above evidence, we suggest that synergistical analgesia effect of MZL and Ropi depended on enhancing independent pathways. We showed that either MZL or Ropi could inhibit spinal pSTAT3 and pERK expression with significant inhibition of neurons and neuroglia cell activation in BCP rats. However, MZL rather than Ropi showed selective inhibitory effect on spinal pSTAT3 expression. On the contrary, Ropi predominantly suppressed spinal pERK expression compared with MZL. In addition, the combination of MZL and Ropi produced stronger and longer analgesic effect with lower dose, and showed stronger inhibitory effect on neurons and neuroglia activation.

In light of the available data above, a conservative way to explain this synergistic effect is that Ropi blocks fast voltage-gated sodium channels and further inhibits the spinal pERK expression, then MZL binds to TSPO in the outer membrane of mitochondria and the consequent production of ROS mediated by inhibition of spinal pSTAT3 expression. However, there is a gap between animal research and clinical application, the effective doses of drug that works well in animals is not sure in humans. In addition, the safety doses of drug should be confirmed with considered judgments in different groups.

In conclusion, the major finding of our study shows that MZL and Ropi act synergistically to inhibit BCP in rats. Further study is needed to make sure the safe and effective doses of I.t. MZL and Ropi in humans. We propose that the combination of MZL and Ropi might be a novel strategy for the treatment of BCP.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (nos. 81371112 and 81171050) and Program for Shaanxi Province Key Research Team of Science and Technology Innovation (2012KCT-14).

References


